Cancer Immunotherapy and Biomarkers

Özet henüz yok.

• ZEYNEP HANDE TURNA

Özet henüz yok.

• ZEYNEP HANDE TURNA

BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy w…

• ÖZDEN ALTUNDAĞ

BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy w…

• TUNCAY GÖKSEL

BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…

• MAHMUT GÜMÜŞ

BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…

• MAHMUT GÜMÜŞ

BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…

• FİLİZ ÇAY ŞENLER

Özet henüz yok.

• ZEYNEP HANDE TURNA

Özet henüz yok.

• ÖZGÜR ÖZYILKAN

Özet henüz yok.

• FİLİZ ÇAY ŞENLER
• ÖZDEN ALTUNDAĞ
• TUNCAY GÖKSEL

Özet henüz yok.

• ÖZGÜR ÖZYILKAN

Özet henüz yok.